Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors
- 1 February 2002
- journal article
- review article
- Published by Elsevier BV in Pharmacological Research
- Vol. 45 (2), 73-85
- https://doi.org/10.1006/phrs.2001.0935
Abstract
No abstract availableKeywords
This publication has 132 references indexed in Scilit:
- Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemiaCell Death & Differentiation, 2001
- Suppression of poly (ADP‐ribose) polymerase activation by 3‐aminobenzamide in a rat model of myocardial infarction: long‐term morphological and functional consequencesBritish Journal of Pharmacology, 2001
- A Bidirectional Promoter Connects the Poly(ADP-ribose) Polymerase 2 (PARP-2) Gene to the Gene for RNase P RNAJournal of Biological Chemistry, 2001
- Effects of inhibitors of the activity of poly (ADP‐ribose) synthetase on the liver injury caused by ischaemia‐reperfusion: a comparison with radical scavengersBritish Journal of Pharmacology, 1998
- Protection by Inhibition of Poly (ADP-ribose) Synthetase Against Oxidant Injury in Cardiac MyoblastsIn VitroJournal of Molecular and Cellular Cardiology, 1997
- A survey of telomerase activity in human cancerEuropean Journal Of Cancer, 1997
- Major vault protein LRP-related multidrug resistanceEuropean Journal Of Cancer, 1996
- Poly(ADP‐Ribose) Synthetase Activation: An Early Indicator of Neurotoxic DNA DamageJournal of Neurochemistry, 1995
- Nitric Oxide Toxicity in Islet Cells Involves Poly(ADP-Ribose) Polymerase Activation and Concomitant NAD+ DepletionBiochemical and Biophysical Research Communications, 1994
- 3-Aminobenzamide synergistically increases sister-chromatid exchanges in cells exposed to methyl methanesulfonate but not to ultraviolet lightMutation Research Letters, 1982